While molecular foundation models optimize drug candidates in silico, they cannot foresee human clinical outcomes. By running protocol criteria against cohorts of simulated real-world patients, study teams can forecast average endpoint effects and adverse event probabilities before enrolling patients.
Mathematical explainability approaches like SHAP values and ablation studies are insufficient to build trust with clinical experts. Life sciences models must generate qualitative reasoning traces that mirror clinical rationale, which can then be validated against subject matter expertise to confirm sound decision-making.
Internal scenario testing allows for some statistical uncertainty to narrow broad portfolio risks, but regulatory submissions demand much higher rigor. Generating synthetic control arms or digital twins requires close collaboration with biostatisticians and epidemiologists to statistically mirror real patient distributions.
General large language models trained on internet data lack life sciences patterns, resulting in low accuracy when forecasting clinical trial success. Post-training models on millions of longitudinal patient records and historical trials enables accurate predictions of medical outcomes and adverse events.
Just as language models use embeddings to predict the next token, life sciences models map patients, diseases, and endpoints into relational vectors. This internal world model allows algorithms to forecast sequential health events, disease diagnoses, and patient-specific biomarker responses to targeted therapies.